Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - follitropin alfa, quantity: 150 iu; lutropin alfa, quantity: 75 iu - injection, powder for - excipient ingredients: sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate monohydrate; methionine; polysorbate 20; phosphoric acid; sodium hydroxide - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency.

Israel - English - Ministry of Health

merck serono ltd - follitropin alfa - solution for injection - follitropin alfa 600 iu/ml - follitropin alfa - follitropin alfa - in adult women:• anovulation (including polycystic ovarian disease, pcod) in women who have been unresponsive to treatment with clomiphene citrate.• stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertilisation (ivf), gamete intra-fallopian transfer (gift) and zygote intra-fallopian transfer (zift).• follitropin alfa in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level < 1.2 iu/l.in adult men:• follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hcg) therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - follitropin delta, quantity: 72 microgram - injection, solution - excipient ingredients: phenol; methionine; sodium sulfate decahydrate; dibasic sodium phosphate dodecahydrate; polysorbate 20; phosphoric acid; sodium hydroxide; water for injections - controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (art) such as an in vitro fertilisation (ivf) or intracytoplasmic sperm injection (icsi) cycle.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - follitropin delta, quantity: 36 microgram - injection, solution - excipient ingredients: phenol; methionine; sodium sulfate decahydrate; dibasic sodium phosphate dodecahydrate; polysorbate 20; phosphoric acid; sodium hydroxide; water for injections - controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (art) such as an in vitro fertilisation (ivf) or intracytoplasmic sperm injection (icsi) cycle.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - follitropin delta, quantity: 12 microgram - injection, solution - excipient ingredients: phenol; methionine; sodium sulfate decahydrate; dibasic sodium phosphate dodecahydrate; polysorbate 20; phosphoric acid; sodium hydroxide; water for injections - controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (art) such as an in vitro fertilisation (ivf) or intracytoplasmic sperm injection (icsi) cycle.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - corifollitropin alfa, quantity: 0.2 mg/ml - injection, solution - excipient ingredients: sodium citrate dihydrate; sodium hydroxide; sucrose; polysorbate 20; water for injections; methionine; hydrochloric acid - controlled ovarian stimulation (cos) for the development of multiple follicles and pregnancy in women undergoing in-vitro fertilisation techniques.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - corifollitropin alfa, quantity: 0.3 mg/ml - injection, solution - excipient ingredients: sodium citrate dihydrate; sucrose; hydrochloric acid; polysorbate 20; water for injections; sodium hydroxide; methionine - controlled ovarian stimulation (cos) for the development of multiple follicles and pregnancy in women undergoing in-vitro fertilisation techniques.

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - follitropin (unii: 076whw89tw) (follitropin - unii:076whw89tw) - follitropin 350 [iu] in 0.42 ml - follistim® aq cartridge (follitropin beta) injection, is indicated: in women for: prior to initiation of treatment with follistim aq cartridge: - women should have a complete gynecologic and endocrinologic evaluation. - primary ovarian failure should be excluded. - the possibility of pregnancy should be excluded. - tubal patency should be demonstrated. - the fertility status of the male partner should be evaluated. prior to initiation of treatment with follistim aq cartridge: - women should have a complete gynecologic and endocrinologic evaluation and diagnosis of cause of infertility. - the possibility of pregnancy should be excluded. - the fertility status of the male partner should be evaluated. in men for: prior to initiation of treatment with follistim aq cartridge: - men should have a complete medical and endocrinologic evaluation. - hypogonadotropic hypogonadism should be confirmed and primary testicular failure should be excluded. - serum testosterone levels should be normalized with human chorionic

Australia - English - Department of Health (Therapeutic Goods Administration)

gedeon richter australia pty ltd - follitropin alfa, quantity: 300 iu - injection, solution - excipient ingredients: poloxamer; sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; methionine; phosphoric acid; thymidine; trypsin - in adult women:,- afolia is indicated for the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated,- controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies,- afolia in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level <1.2 iu/l.,in adult men:,- afolia is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

Australia - English - Department of Health (Therapeutic Goods Administration)

gedeon richter australia pty ltd - follitropin alfa, quantity: 225 iu - injection, solution - excipient ingredients: poloxamer; sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; methionine; phosphoric acid; thymidine; trypsin - in adult women:,- afolia is indicated for the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated,- controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies,- afolia in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level <1.2 iu/l.,in adult men:,- afolia is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.